EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis

Hon Jen Wong, Norman H Lin, Yao Neng Teo, Nicholas L Syn, Yao Hao Teo, Ching-Hui Sia

American Journal of Cardiovascular Drugs · 2024-05 · 24 (3) · 371-383

DOI: 10.1007/s40256-024-00640-w ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 08.04.2024. Verfasst von Hon Jen Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Metformin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Metformin and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated cardiovascular benefits but their comparative effects on mortality in type 2 diabetes mellitus (T2DM) patients with cardiovascular disease (CVD) are unknown. Hence, we evaluated and compared lifetime benefits arising from metformin or SGLT2 inhibitors in T2DM patients with CVD. MATERIALS AND METHODS: Studies published in the PubMed, EMBASE and CENTRAL databases before 28 October 2023 were retrieved. Treatment effects of metformin against US FDA-approved SGLT2 inhibitors in T2DM patients with CVD were evaluated and lifetime gains in event-free survival were estimated from our primary endpoints of all-cause and cardiovascular mortality. Risk ratios were derived to assess their impact on secondary outcomes such as major adverse cardiovascular events and hospitalizations for heart failure. RESULTS: Overall, 14 studies were included. Five studies published Kaplan-Meier curves for the primary outcome of all-cause mortality. Individual participant data were reconstructed from these Kaplan-Meier curves, from which we conducted our two-stage meta-analysis. Participants receiving metformin and SGLT2 inhibitors experienced a reduction in the risk for all-cause mortality as compared with those not taking metformin and placebo. However, participants receiving SGLT2 inhibitors had a higher all-cause mortality (hazard ratio 1.308, 95% confidence interval 1.103-1.550) versus metformin. Treatment with metformin was estimated to offer an additional 23.26 months of survival free from all-cause mortality versus 23.04 months with SGLT2 inhibitors. CONCLUSIONS: In patients with T2DM and CVD, metformin and SGLT2 inhibitors were associated with substantially lower all-cause mortality rates and slightly longer life expectancies than in patients without. Metformin presented an advantage over SGLT2 inhibitors in reducing all-cause mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesMetforminHypoglycemic AgentsHumans

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Cardiology, National University Heart Centre Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 9, Singapore, 119228, Singapore.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ching_hui_sia@nuhs.edu.sg.
  • Department of Cardiology, National University Heart Centre Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 9, Singapore, 119228, Singapore. ching_hui_sia@nuhs.edu.sg.

Zitieren

APA

Wong, H. J., Lin, N. H., Teo, Y. N., Syn, N. L., Teo, Y. H., & Sia, C. H. (2024). Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis. American Journal of Cardiovascular Drugs, 24(3), 371-383. https://doi.org/10.1007/s40256-024-00640-w

Vancouver

Wong HJ, Lin NH, Teo YN, Syn NL, Teo YH, Sia CH. Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis. American Journal of Cardiovascular Drugs. 2024;24(3):371-383. doi:10.1007/s40256-024-00640-w

BibTeX
@article{Wong2024,
  author = {Wong, Hon Jen and Lin, Norman H and Teo, Yao Neng and Syn, Nicholas L and Teo, Yao Hao and Sia, Ching-Hui},
  title = {Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2024},
  volume = {24},
  number = {3},
  pages = {371--383},
  doi = {10.1007/s40256-024-00640-w}
}
Kostenlos starten →